Traders purchased shares of Thermo Fisher Scientific Inc. (NYSE:TMO) on weakness during trading on Friday. $231.09 million flowed into the stock on the tick-up and $69.29 million flowed out of the stock on the tick-down, for a money net flow of $161.80 million into the stock. Of all companies tracked, Thermo Fisher Scientific had the 23rd highest net in-flow for the day. Thermo Fisher Scientific traded down ($2.01) for the day and closed at $210.44
A number of equities research analysts have recently weighed in on the company. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Leerink Swann restated an “outperform” rating and set a $239.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. Barclays lifted their price target on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Finally, BTIG Research started coverage on Thermo Fisher Scientific in a research report on Friday, January 5th. They set a “buy” rating and a $230.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $220.50.
The company has a current ratio of 1.34, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74. The stock has a market cap of $85,130.00, a PE ratio of 34.44, a price-to-earnings-growth ratio of 1.56 and a beta of 1.15.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the company posted $2.41 earnings per share. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.32%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date is Wednesday, March 14th. Thermo Fisher Scientific’s payout ratio is 11.13%.
In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $204.60, for a total value of $511,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William G. Parrett sold 1,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $209.80, for a total value of $209,800.00. The disclosure for this sale can be found here. Insiders sold 48,827 shares of company stock worth $10,606,272 over the last three months. Corporate insiders own 0.49% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Icon Wealth Partners LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $105,000. Bank of Nova Scotia Trust Co. bought a new stake in Thermo Fisher Scientific in the third quarter worth $106,000. Keeler Thomas Management LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $106,000. Virtue Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $127,000. Finally, Premia Global Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $131,000. 87.67% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/16/traders-buy-shares-of-thermo-fisher-scientific-tmo-on-weakness.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.